Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002806481 | SCV003196691 | uncertain significance | Bloom syndrome | 2022-09-23 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 244 of the BLM protein (p.Ala244Val). This variant is present in population databases (rs771809777, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with BLM-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. |
Ambry Genetics | RCV004948779 | SCV005538081 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-09-06 | criteria provided, single submitter | clinical testing | The c.731C>T (p.A244V) alteration is located in exon 3 (coding exon 2) of the BLM gene. This alteration results from a C to T substitution at nucleotide position 731, causing the alanine (A) at amino acid position 244 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |